Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL